Menlo Therapeutics Inc. (MNLO)
(Delayed Data from NSDQ)
$6.96 USD
-0.04 (-0.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
VYNE Therapeutics Inc. [MNLO]
Reports for Purchase
Showing records 1 - 20 ( 49 total )
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Amzeeq Ramping Again and Zilxi on Track for 4Q Launch; Lower PT to $3 on Greater Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ZILXI (FMX103) Approved; AMZEEQ Bouncing Back From COVID Faster Than We Expected; Raise to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Looking Forward to Post-COVID AMZEEQ Ramp and June 2 FMX103 PDUFA
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Serlo Phase 3s Miss; Lower to $2 on Serlo Removal and Dilution, But Maintain Buy on AMZEEQ Post-COVID Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q19; Serlo PN Phase 3 Imminent; More Conservative Year-1 AMZEEQ and Higher Spend Has Us Tweak Target to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Modeling a Merged Commercial-Stage Menlo; Reiterate Buy with Pro Forma $10 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 75.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Part 3: Expert Call Recap for 2019 in Rare Disease
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Price: 10.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Price: 10.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q19 - CPUO in Early 1Q20 Will Pull Back the Curtain Ahead of PN Readout
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Analyst Day Outline Liftoff in PN and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Crucial Serlopitant Catalysts Closing In; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 75.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from our Doc Call with Dr. Andrew Alexis
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Price: 25.00
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00